g kishan reddy people page on Anadi Algo News

Monday, June 15, 2026
DISCLAIMER: AI-generated signals are for informational purposes only. All trading and investment decisions are solely the user's responsibility.|Past performance does not guarantee future results. Trade at your own risk.|Anadi Algo is not a SEBI-registered advisor. Consult a qualified financial advisor before acting on any recommendation.|DISCLAIMER: AI-generated signals are for informational purposes only. All trading and investment decisions are solely the user's responsibility.|Past performance does not guarantee future results. Trade at your own risk.|Anadi Algo is not a SEBI-registered advisor. Consult a qualified financial advisor before acting on any recommendation.|
AnadiAlgoNews
सट्टा नहीं, सिस्टम
People Landing|80 matching stories

g kishan reddy News, Mentions & Market Context

AI-analyzed market coverage and mentions for g kishan reddy, including related stories and trading context.

What Traders Do Next

g kishan reddy is more useful with a process around it.

Use these pages to understand the story first. Execution usually comes later, after the idea is filtered, tested, and sized correctly.

Translate It into Rules

See how a market theme can turn into a structured workflow instead of impulse.

Check the Setup

Use a validation step before any trade decision starts feeling obvious.

Read the Main Algo Guide

Start broad if you want to understand the workflow before you optimize the setup.

This is here if you want to go deeper, not as a push.Explore Anadi
Top Story|et_economy1 day ago

Electronics, pharma and engineering goods lead India's FTA dividend as export engine shifts gears

The pharma sector is currently influenced by rupee weakness and defensive buying, alongside patent wins and tariff risks. This news adds a positive export-driven growth dimension.

buy
Bullish+7590%
ElectronicsEngineeringPharmaceuticals
+75

Impact Score

Affected Stocks

Electronics Manufacturing Companies
Positive
Engineering & Machinery Companies
Positive
Pharmaceutical Companies
Positive
Consider a long bias on fundamentally strong Indian pharma stocks with a focus on export markets, maintaining strict risk discipline given regulatory and pricing pressures.
et_companies5 days ago

Hetero partners with Richter to develop, market Semaglutide injection globally

Indian pharma is focusing on complex generics and biosimilars for global markets. Semaglutide is a high-value drug.

hold
Bullish+48.295%
5 factsDRLSUNPHARMA
Positive bias for Indian pharma companies with strong R&D and global market access.|Quick check: DRL neutral, SUNPHARMA neutral (oversold).
et_economy6 days ago

Centre announces Rs 95,692 crore interim allocation under VB-G RAM G

Government spending on rural employment and infrastructure is a key driver for rural consumption and related industries. This large allocation provides a strong tailwind.

hold
Bullish+46.280%
5 facts
Long bias for companies with strong rural market presence and those in the infrastructure/construction materials sector.|Quick check: MARUTI neutral (+0.6% 1d), TATAMOTORS bearish bias (-2.4% 1d).
et_companies7 days ago

Centre has coal reserves for 80 days of power generation: Union Minister Kishan Reddy

The power sector is currently focused on ensuring stable and affordable electricity supply to meet growing industrial and domestic demand. Assured coal reserves are critical for thermal power plants, which form the backbone of India's energy mix.

hold
Bullish+46.190%
5 factsPOWERGRIDCOALINDIAADANIPOWER
Maintain a bullish bias on power generation and coal mining stocks, looking for entry points on minor pullbacks, with a focus on companies with strong operational efficiency.|Quick check: POWERGRID bearish bias (+0.1% 1d), COALINDIA neutral (-2.0% 1d).

Latest g kishan reddy Mentions

livemint_markets7 days ago+42.6

Sun Pharma, Alkem Labs, other pharma stocks gain despite stock market crash; Nifty Pharma rises for fourth day in a row

sell5 factsSUNPHARMAALKEMJBCCHEMPharmaceuticals
Maintain a bullish bias on the pharma sector; consider long positions in fundamentally strong companies with good product pipelines and stable regulatory standing, with strict stop-losses below key support levels.|Quick check: SUNPHARMA bearish bias (oversold), ALKEM bearish bias (-0.4% 1d).
livemint_markets7 days ago+10.9

SMR Jewels share price gains after listing with 20% discount on BSE SME

hold5 factsJewellerySME IPOs
Maintain a bullish bias on established pharma players like Dr. Reddy's and Cipla, focusing on strong pipelines and USFDA approvals, with strict stop-losses.|Quick check: SUNPHARMA bearish bias (oversold), CIPLA neutral (+0.0% 1d).
et_markets9 days ago+40.6

Stock pickers’ market ahead as RBI flags risks; largecaps, banks and capex plays offer value: George Thomas

hold5 factsHDFCBANKICICIBANKSBINBankingHealthcare
Given the recommendation for banks, focus on large-cap private and public sector banks with strong asset quality and stable NIMs, considering potential long-term value despite short-term headwinds. Maintain strict stop-losses.|Quick check: HDFCBANK bearish bias (-0.7% 1d), ICICIBANK neutral (+0.6% 1d).
et_markets11 days ago-15.2

Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories weekly performance shows decline

hold3 factsDRLbroad_market
Maintain a cautious or bearish bias on DRL in the short term.|Quick check: DRL neutral, NIFTY neutral.
et_markets12 days ago+6.2

Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories shows low beta, indicating stability.

hold3 factsDRLbroad_marketpharma
Neutral, but attractive for defensive positioning. Consider for long-term, stable growth.|Quick check: DRL neutral, NIFTY neutral.
et_companies13 days ago+36.8

Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight loss

sell5 factsALKEMLUPINDRLpharma
Bullish on ALKEM; monitor market share gains and competitor reactions.|Quick check: ALKEM bearish bias (-1.3% 1d), LUPIN neutral (-0.1% 1d).
et_markets13 days ago-2.1

Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories trading volume report

sell4 factsDRLbroad_market
Observe price direction with volume; high volume on up move is bullish, on down move is bearish.|Quick check: DRL neutral, NIFTY bearish bias (-27.5% 1d).
et_companies14 days ago+25.4

GVK-backed Oval Fertility launched in Hyderabad, eyes share in India's growing IVF market

5 factsHealthcareHospitals & Diagnostics
Maintain a bullish bias on healthcare stocks with strong balance sheets and diversified service offerings, particularly those with potential to enter or expand in specialized segments like fertility.|Quick check: MARUTI neutral (-0.4% 1d), TATAMOTORS bullish bias (-0.1% 1d).
et_markets14 days ago-50.9

These 7 stocks reported declining EPS for 4 straight quarters

hold5 factsDRREDDYGAILTORNTPOWERPharmaceuticalsOil & Gas
Maintain a cautious stance on the mentioned stocks and their respective sectors; consider short-term bearish trades or avoiding long positions until a clear turnaround in profitability is evident.|Quick check: DRREDDY neutral (+0.2% 1d), GAIL bullish bias (-0.2% 1d).
livemint_companies17 days ago+43.1

Tata Capital may part exit as Anderson Diagnostics looks to raise ₹250 crore in a fresh round

hold5 factsDRLLUPINHealthcarePharmaceuticals
Maintain a bullish bias on established Indian pharma and diagnostic stocks, focusing on companies with strong balance sheets and growth prospects, with disciplined risk management.|Quick check: DRL neutral, LUPIN neutral (+0.0% 1d).
et_markets17 days ago-4.3

Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories shows resilience with 3M returns

hold3 factsDRLbroad_market
No trade setup possible from this article.|Quick check: DRL neutral, NIFTY bearish bias (oversold).
et_companies18 days ago+64.8

India poised for critical mineral breakthrough within a year, says Minister G Kishan Reddy

5 factsmetalsmining
Long-term bullish bias for sectors consuming critical minerals; look for companies with strong R&D in material science or those expanding into related processing.|Quick check: TATASTEEL neutral (+0.0% 1d), HINDALCO bullish bias (overbought).
et_companies19 days ago+62

Tata-backed MedTherapy claims CAR-T breakthrough with one-day production

buy5 factsTATACHEMTATASTEELDRLPharmaceuticalsBiotechnology
Consider a long bias on select Tata Group entities with healthcare exposure, and monitor major Indian pharma stocks for strategic shifts towards biotech innovation, with a stop-loss below recent support levels.|Quick check: TATACHEM neutral (-1.0% 1d), TATASTEEL bullish bias (+2.0% 1d).
et_markets19 days ago+8.8

Dr Reddys Share Price Live Updates: Dr. Reddys News

hold5 factsDRLPharmaceuticals
For DRL, maintain a neutral to slightly bearish bias given recent negative news, but be prepared for short-term bounces. Use strict stop-losses.|Quick check: DRL neutral, NIFTY neutral.
et_markets20 days ago-39.5

Market Wrap: Sensex falls 479 points, Nifty below 23,950 as bank stocks falter; small, midcaps shine

buy5 factsHDFCBANKICICIBANKRELIANCEBankingOil & Gas
Maintain a cautious bias on banking stocks; consider short-term bearish positions or hedging strategies, while selectively looking for opportunities in resilient midcap and smallcap segments.|Quick check: HDFCBANK neutral (-0.9% 1d), ICICIBANK bullish bias (-1.0% 1d).
et_companies24 days ago-22.8

Pregabalin moved to Schedule H1 as centre cracks down on drug misuse

buy5 factsDRLpharma
Negative bias for pharma companies with high exposure to Pregabalin sales.|Quick check: DRL neutral, SUNPHARMA bullish bias (+0.3% 1d).
et_markets25 days ago+55.8

IT a tactical buy; Devarsh Vakil reveals 5 sectors worth buying as markets turn volatile

hold5 factsTCSINFYWIPROInformation TechnologyPower
Long positions in fundamentally strong banking stocks are favored, with a bias towards those demonstrating robust credit growth and improving asset quality.|Quick check: TCS bearish bias (-0.3% 1d), INFY bullish bias (-0.4% 1d).
livemint_markets25 days ago+36.7

Stocks to watch: LIC, ITC, RVNL, Dr Reddy's among 10 shares in focus today; check list here

hold5 factsLICITCRVNLbroad_market
Look for early momentum in these stocks; consider long positions if positive sentiment holds, with strict stop-losses.|Quick check: LIC neutral, ITC neutral (-0.9% 1d).
et_companies26 days ago-18.3

No cosmetic job with jabs, warns drug regulator CDSCO

hold5 factsDRLCIPLApharma
Cautious to bearish bias for pharma companies with aesthetic product exposure; monitor regulatory updates.|Quick check: DRL neutral, CIPLA bullish bias (-0.6% 1d).
et_companies26 days ago+55

Dr Reddy’s launches oral semaglutide in India

buy5 factsDRLpharma
Positive bias for DRL. Look for sustained volume growth and market penetration for Obeda.|Quick check: DRL neutral, SUNPHARMA bullish bias (-0.1% 1d).
et_companies26 days ago+44.6

Dr Reddy's launches oral semaglutide biosimilar Obeda in India

hold5 factsDRLLUPINSUNPHARMApharmaceuticals
Positive bias for DRL; monitor sales trajectory and competitive landscape.|Quick check: DRL neutral, LUPIN neutral (-0.4% 1d).
et_companies28 days ago-27.2

Rising input costs, export slump take a toll on drug companies' health

buy5 factsSUNPHARMADRLCIPLApharma
Bearish outlook for the pharmaceutical sector; potential for margin contraction.|Quick check: SUNPHARMA bullish bias (+1.4% 1d), DRL neutral.
et_companiesabout 1 month ago+59.1

Dr Reddy’s launches generic Semaglutide injection, popular weight-loss drug, in Canada

buy5 factsDRLpharma
Positive bias for DRL; look for sustained volume and revenue growth from this new product.|Quick check: DRL neutral, SUNPHARMA bullish bias (+0.9% 1d).
et_marketsabout 1 month ago+51.4

Markets choppy, inflation looming: Pashupati Advani on what should investors do now

hold5 factsSUNPHARMADRLInfrastructurePharmaceuticals
Consider long positions in fundamentally strong pharma companies with robust pipelines and good regulatory standing, maintaining strict stop-losses.|Quick check: SUNPHARMA bullish bias (-1.1% 1d), DRL neutral.
livemint_companiesabout 1 month ago+67.1

Cipla bets on fast-growing biosimilars market, to steadily add products: CEO

buy5 factsCIPLADRLBIOCONPharmaceuticalsHealthcare
Maintain a bullish bias on Indian pharma stocks with strong R&D and biosimilar pipelines, with a focus on companies demonstrating successful product launches and regulatory approvals.|Quick check: CIPLA bullish bias (+2.8% 1d), DRL neutral.
livemint_marketsabout 1 month ago-57.8

Dr Reddy's Laboratories shares volatile after an 86% YoY decline in Q4 profit. Should you buy?

hold5 factsDRLPharmaceuticals
Given the negative news for DRL, a bearish bias is warranted for the stock; consider short-term downside plays with strict stop-losses.|Quick check: DRL neutral, NIFTY neutral.
et_marketsabout 1 month ago-49.1

Dr Reddy's shares in focus after Q4 net profit tumbles 86% YoY; Morgan Stanley, Goldman Sachs weigh in

hold5 factsDRLPharmaceuticals
Maintain a cautious stance on DRL; consider short positions or avoiding fresh long entries until clarity emerges on profitability drivers.|Quick check: DRL neutral, SUNPHARMA bullish bias (overbought).
et_marketsabout 1 month ago-60.7

Dr Reddy's Laboratories Q4 Results: Cons PAT falls 86% YoY to Rs 221 crore, revenue dips 12%; Rs 8 per share dividend announced

hold5 factsDRLPharmaceuticals
Given Dr. Reddy's significant earnings miss, a bearish bias is warranted for DRL. Traders should look for confirmation of downside momentum and manage risk with strict stop-losses.|Quick check: DRL neutral, MARUTI bearish bias (-2.3% 1d).
livemint_marketsabout 1 month ago-60.1

Dr Reddy's Q4 results 2026: Profit plunges 86% YoY to ₹220 crore; board recommends a final dividend of ₹8

hold4 factsDRLPharmaceuticals
Maintain a cautious to bearish bias on DRL; consider shorting opportunities with strict stop-losses above recent resistance levels.|Quick check: DRL neutral, TATASTEEL neutral (-0.2% 1d).
livemint_marketsabout 1 month ago+38.2

Stocks to buy: Sagar Doshi suggests Dr Reddys, Grasim, and HUL shares to buy

buy5 factsGRASIMPharmaceuticalsDiversified
Given the rising crude prices, consider a bearish bias for oil marketing companies (OMCs) and industries with high energy consumption, while looking for defensive plays or companies with pricing power.|Quick check: GRASIM bullish bias (overbought), NIFTY neutral.
livemint_marketsabout 1 month ago+42.6

Q4 results 2026: Tata Power to Dr Reddy's among companies to declare Q4 results today; full list here

hold5 factsTATAPOWERDRLPowerPharmaceuticals
For auto stocks, maintain a bearish bias given recent declines; look for confirmation in Q4 results regarding volume growth and discounting pressures.|Quick check: TATAPOWER neutral (oversold), DRL neutral.
et_economyabout 1 month ago+35.4

From dry lands to thriving farms: How one farmer from Andhra transformed dry land into productive crops worth crores

hold5 factsJISLJALEQSmetalsagriculture
Positive bias for agri-tech, irrigation, and specialized agrochemical companies; watch for government support for sustainable farming.|Quick check: JISLJALEQS neutral, TATASTEEL neutral (-1.1% 1d).
et_economyabout 1 month ago+50.5

Explained: What is the new VB-G RAM G Act and how will it replace MGNREGA?

5 factsConstructionCement
Look for opportunities in sectors directly benefiting from rural infrastructure and consumption, with a bullish bias on cement and select auto/consumer stocks. Maintain strict stop-losses.|Quick check: NIFTY neutral, BANKNIFTY neutral.
et_economyabout 1 month ago+57.8

Govt to replace MGNREGA with new rural jobs scheme G RAM G, guarantees 125 days of work at near Rs 96,000 crore budget allocation

5 factsFMCGCement
Consider a bullish bias for companies with significant exposure to the rural economy, particularly in FMCG, cement, and consumer durables.|Quick check: TATASTEEL neutral (-0.1% 1d), HINDALCO neutral (+0.0% 1d).
et_companiesabout 1 month ago+32.6

Chinese medicines bring relief to India’s cancer patients

hold5 factsDRREDDYPharmaceuticalsHealthcare
Maintain a cautious bias on Indian pharma stocks with high exposure to branded oncology drugs, looking for signs of strategic adaptation or pricing pressure.|Quick check: DRREDDY neutral (oversold), SUNPHARMA bullish bias (overbought).
et_companiesabout 1 month ago+45

Dr Reddy's and Nestle Health Science strengthen presence in diabetes, obesity nutrition space

hold5 factsDRLpharmaceuticalshealthcare
Positive bias for DRL; look for sustained volume and price action above recent resistance levels.|Quick check: DRL neutral.
et_companiesabout 1 month ago+61.6

Telangana govt seeks Centre’s approval for Rs 38,595-crore Hyderabad Metro Phase-II project

5 factsinfrastructureconstruction
Identify infrastructure companies with strong execution capabilities and a track record in metro projects for potential long positions.|Quick check: SUNPHARMA bullish bias (overbought), CIPLA bullish bias (overbought).
et_companiesabout 1 month ago+52.6

Emcure eyes India growth, global deals amid strong demand

hold5 factsLUPINDRLPharmaceuticals
Maintain a bullish bias on Indian pharma stocks, focusing on companies with strong product pipelines and global expansion strategies, with strict risk management.|Quick check: LUPIN bullish bias (-0.5% 1d), DRL neutral.
livemint_marketsabout 1 month ago-48.9

DMart shares tumble 4% after Q4 results, wipe off ₹9,300 crore from Radhakishan Damani & other promoters' wealth

hold5 factsDMARTRetailFMCG
Given the negative reaction, traders might look for shorting opportunities in DMART or similar retail stocks if broader market sentiment remains weak, with strict stop-losses.|Quick check: DMART bullish bias (+0.5% 1d), TATASTEEL neutral (-2.2% 1d).
et_companiesabout 1 month ago+42

Two separate venues for pharma industry expos in Delhi-NCR

buy5 factsSUNPHARMADRREDDYCIPLApharmahealthcare
Maintain a bullish bias on Indian pharmaceutical stocks, especially those with strong API and formulation capabilities.|Quick check: SUNPHARMA bullish bias (+2.1% 1d), DRREDDY bullish bias (overbought).
et_marketsabout 2 months ago-59

Rupee hits all-time low of 95.23 vs USD, pummelled by oil surge, Fed's hawkish tilt

hold5 factsIOCONGCOil & GasIT Services
Favor export-oriented pharma stocks with strong US presence (e.g., Dr. Reddy's, Cipla) for potential upside, while being cautious on those heavily reliant on imported APIs or domestic sales.|Quick check: IOC bearish bias (-0.9% 1d), ONGC bullish bias (overbought).
et_marketsabout 2 months ago-61.2

Why is market falling today? Sensex slumps over 900 points, Nifty below 23,900; 7 key factors

hold5 factsNIFTYSENSEXEquity MarketOil & Gas
Consider a long bias in select pharma stocks with strong fundamentals and positive news flow, while maintaining strict stop-losses due to overall market volatility.|Quick check: NIFTY neutral, SENSEX neutral.
et_companiesabout 2 months ago+58.9

Dr Reddy’s Laboratories receives approval from Health Canada for its generic semaglutide injection

hold5 factsDRLPharmaceuticals
Maintain a bullish bias on DRL, looking for sustained upward momentum. Consider entry points on minor pullbacks with a stop-loss below recent support levels.|Quick check: DRL neutral, MARUTI bullish bias (+2.9% 1d).
et_companiesabout 2 months ago+46.9

Dr Reddy's gets Health Canada nod for generic semaglutide injection

sell5 factsDRLPharmaceuticals
Maintain a bullish bias on DRL, looking for entry points on dips, with a focus on volume and price action post-launch announcements.|Quick check: DRL neutral, MARUTI bearish bias (-2.5% 1d).
et_economyabout 2 months ago+54.4

India–New Zealand $20 billion FTA: List of sectors set to gain ground as the deal kicks in

hold5 factsARVINDBATAINDIASUNPHARMApharma
Long positions in export-oriented textile, leather, and pharmaceutical companies. Focus on companies with established international presence or strong product portfolios.|Quick check: ARVIND neutral, BATAINDIA neutral (-0.7% 1d).
et_economyabout 2 months ago+63

India–New Zealand sign 'once-in-a-generation' FTA

buy5 factsDRLTextilesLeather
Long bias for Indian pharma stocks with strong export capabilities; maintain strict stop-losses given general market volatility.|Quick check: DRL neutral, CIPLA bullish bias (overbought).
et_economyabout 2 months ago+63

India-New Zealand FTA to give major boost to exports: Experts

buy5 factsDRLCIPLAManufacturingPharmaceuticals
Consider a long bias on established Indian pharmaceutical companies with strong export capabilities, focusing on those with diverse product portfolios.|Quick check: DRL neutral, CIPLA bullish bias (overbought).
livemint_marketsabout 2 months ago+76.6

Top Gainers & Losers on April 27: Sun Pharma, Varun Beverages, Suzlon Energy, Anant Raj among top gainers

buy5 factsSUNPHARMAVBLSUZLONInformation TechnologyPharmaceuticals
Consider a bullish bias for select pharma stocks with strong pipelines and export exposure; maintain strict stop-losses below recent support levels.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), VBL bullish bias (overbought).
et_companiesabout 2 months ago+55.8

Sun Pharma: How a small Kolkata trader became a global buyout artist

sell5 factsSUNPHARMADRLCIPLAPharmaceuticals
Maintain a bullish bias on SUNPHARMA, but monitor for potential integration challenges and debt implications post-acquisition. Consider long positions with defined risk management.|Quick check: SUNPHARMA bearish bias (-3.6% 1d), DRL neutral.
livemint_companiesabout 2 months ago+48.3

Sun-Organon buyout shows Indian Pharma's big hunger for overseas M&As — Here's a list of other major deals

sell5 factsSUNPHARMADRLLUPINPharmaceuticals
Maintain a bullish bias on large-cap Indian pharma stocks with strong R&D and M&A capabilities, setting stop-losses below recent support levels.|Quick check: SUNPHARMA bearish bias (-3.6% 1d), DRL neutral.
et_companiesabout 2 months ago+57.5

ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till date

sell5 factsSUNPHARMADRLLUPINPharmaceuticals
Maintain a bullish bias on large-cap Indian pharma stocks, particularly those with strong balance sheets and global ambitions, with a focus on M&A-driven growth. Risk discipline is crucial given the high debt component in such large deals.|Quick check: SUNPHARMA bearish bias (-3.6% 1d), DRL neutral.
et_marketsabout 2 months ago-54

Dalal Street Week Ahead: Nifty’s next big move hinges on support test; volatility set to stay high

hold5 factsNIFTYDRLNATCOPHARMEquity MarketPharmaceuticals
Consider a cautious, range-bound trading strategy for the Nifty, with a bearish bias if 23,800 is breached. Look for opportunities in defensive pharma stocks on dips, but with strict stop-losses.|Quick check: NIFTY neutral, DRL neutral.
et_marketsabout 2 months ago+52.7

Concurrent Gainers: 12 stocks that gained for 5 straight sessions

buy5 factsWELCORPDRLPharmaceuticalsInfrastructure
Consider long positions in fundamentally strong pharma stocks with positive news flow, maintaining strict stop-losses due to overall market volatility.|Quick check: WELCORP bullish bias (overbought), DRL neutral.
et_marketsabout 2 months ago-53.7

Dr Reddy’s shares fall 2% after Goldman Sachs downgrades, Citi turns cautious

5 factsPharmaceuticals
Given the negative analyst sentiment and broader market weakness, a bearish bias for DRL is warranted; consider short positions with tight stop-losses above recent resistance levels.|Quick check: SENSEX neutral, NIFTY neutral.
et_marketsabout 2 months ago+48.8

Dr. Reddy’s among 4 stocks showing bullish RSI upswing

buy5 factsDRREDDYauto
Consider long positions in Dr. Reddy's and other identified stocks, with confirmation from price action and volume.|Quick check: DRREDDY bullish bias (overbought), NIFTY neutral.
et_marketsabout 2 months ago+57.5

Market Trading Guide: Buy Dr Reddy’s Laboratories and Solar Industries on Friday for gains up to 14%

buy5 factsDRLSOLARINDSPharmaceuticalsChemicals
Maintain a selective bullish bias on individual stocks exhibiting strong technicals and volume, while being mindful of broader market resistance and employing strict risk management.|Quick check: DRL neutral, SOLARINDS bullish bias (overbought).
et_marketsabout 2 months ago-29.9

Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories faces a challenging month

hold3 factsDRLPharmaceuticals
Given the 'challenging month' for DRL, a bearish bias is warranted for the stock in the short term, with strict stop-losses.|Quick check: DRL neutral, NIFTY neutral.
et_companiesabout 2 months ago+32.8

Warangal airport foundation stone to be laid soon: Telangana minister

hold5 factsGMRINFRAInfrastructureConstruction
Maintain a bullish bias on infrastructure and construction stocks, focusing on companies with a strong track record in airport development. Implement strict risk management, as project delays or cost overruns can impact profitability.|Quick check: GMRINFRA neutral, INDIGO bullish bias (+0.0% 1d).
et_marketsabout 2 months ago+46.1

10 smallcap stocks ace investors Mukul Agrawal, Ashish Kacholia, Radhakishan Damani bought in Q4

5 factsSmallcapEquity Markets
Look for accumulation in quality smallcap stocks, especially those favored by known ace investors, with a long-term bullish bias and strict stop-losses.|Quick check: NIFTY neutral, BANKNIFTY neutral.
livemint_marketsabout 2 months ago+58.9

VST Industries shares surge 19%: What's behind the rally in this Radhakishan Damani-owned stock?

hold5 factsVSTINDITCGODFRYPHLPFMCGTobacco
Look for momentum plays in fundamentally strong companies within defensive sectors like tobacco, but maintain strict stop-losses given the overall market volatility.|Quick check: VSTIND neutral, ITC bullish bias (+0.0% 1d).
livemint_markets2 months ago+38.6

Why did Radhakishan Damani pick stake in this midcap investment stock?

3 factsbroad_market
Await identification of the stock; then, consider long positions with caution due to potential overvaluation.|Quick check: NIFTY neutral, BANKNIFTY neutral.
et_companies2 months ago+54.1

Coal stock adequate for 90 days available: Union Coal Minister Kishan Reddy

hold5 factsPOWERGRIDCOALINDIAPowerMetals & Mining
Maintain a bullish bias on power generation and heavy industry stocks, focusing on companies with strong domestic coal linkages and stable demand outlook.|Quick check: POWERGRID neutral (-0.5% 1d), COALINDIA bearish bias (+0.1% 1d).
et_markets2 months ago+44.7

D-Street superstars go crash hunting: What Ashish Kacholia, Mukul Agrawal and others bought in March quarter?

hold5 factsSmallcapMidcap
Look for opportunities in fundamentally strong smallcap and midcap stocks that have corrected significantly, aligning with the contrarian buying strategy of seasoned investors. Maintain strict stop-losses.|Quick check: NIFTY neutral, BANKNIFTY neutral.
livemint_companies2 months ago-10

Swiggy co-founder Nandan Reddy steps down; Phani Kishan and Rahul Bothra join board in leadership rejig

hold3 factsSWIGGYnew-age techfood delivery
Market has likely priced this in; expect mild sentiment drag on SWIGGY but no fundamental change — watch for follow-through reaction vs ZOMATO relative strength.
et_markets2 months ago+15

The rupee’s swing: When currency becomes the deal maker or breaker

sell4 factsTCSINFYHCLTECHIT ServicesPharmaceuticals
Market has likely priced this in; maintain overweight on export-linked IT/pharma (TCS, INFY, SUNPHARMA) and underweight firms with high unhedged USD debt.
livemint_markets2 months ago-45

US sales may drag pharma companies’ Q4, even as India holds up

hold3 factsCIPLADRREDDYZYDUSLIFEPharmaceuticalsHealthcare
Market has likely priced this in post Q4 results; prefer India-focused pharma (Mankind, JB Chem) over US-heavy names like Cipla, DRREDDY, ZYDUSLIFE on rallies.
et_economy2 months ago+25

India eyes 20 more countries for open market access in next big trade bet

buy4 factsTATASTEELSUNPHARMADRREDDYexportspharma
Bullish medium-term for export-linked names; accumulate pharma (SUNPHARMA, DRREDDY) and engineering (BHARATFORG, LT) on dips — immediate move likely priced in.
et_economy2 months ago+30

India Inc ramps up exports as Iran ceasefire reopens Middle East trade

hold4 factsCIPLADRREDDYSUNPHARMAPharmaceuticalsPackaged Foods
Market has likely priced in the headline already; only add to pharma/FMCG exports on fresh evidence of order growth, margin expansion and customs/export volume acceleration, else stay selective.
et_companies2 months ago+18

Israel-Iran war: India flags crunch in key pharma solvents used for life-saving drugs; govt moves to stabilise supply

hold4 factsDRREDDYSUNPHARMACIPLAPharmaceuticalsSpecialty Chemicals
Market has likely priced this in; wait for official feedstock-allocation updates, and only add selective long bias in quality large-cap pharma on confirmation of normalized supply, with tight stop discipline on any renewed input warning.
et_companies2 months ago+60

Capped LPG allocation cleared for polymer, steel, pharma sectors

sell6 factsRELIANCEJSWSTEELTATASTEELPharmaceuticalsSteel
Bullish for industrial sectors like steel, pharma, and polymers; consider long positions in companies with high LPG consumption.
et_economy2 months ago+10

US envoy to India meets Trump, discusses 'strong future of India-US ties'

sell4 factsTCSINFYDRREDDYInformation TechnologyPharmaceuticals
Market has likely priced in general positive sentiment; focus on specific policy announcements for actionable trades in IT and Pharma.
et_companies2 months ago+40

Corporate India brings health intelligence to the fore as preventive care surges: Report

hold3 factsAPOLLOHOSPDRLLALPATHLABHealthcareDiagnostics
Consider long positions in diagnostic chains and hospital stocks, as corporate focus on employee health drives demand for preventive care services.
et_economy2 months ago-60

Morgan Stanley cuts India’s FY27 growth outlook to 6.2% amid Gulf conflict

sell5 factsSUNPHARMADRREDDYTATACHEMPharmaceuticalsTextiles
Maintain a cautious stance on Indian equities, particularly in import-dependent sectors and those with significant export exposure, and consider defensive plays.
livemint_companies2 months ago+60

Here's what Indian Inc. is projecting for salary increment, promotions, attrition rates, talent development in 2026

sell4 factsHDFCBANKICICIBANKRELIANCEFinancial ServicesManufacturing
Focus on financial services, manufacturing, and pharma stocks for potential upside driven by strong talent investment and consumer demand.
et_companies2 months ago+60

Comm secy asks pharma sector to cut dependence on imported raw materials

hold4 factsSUNPHARMADRREDDYCIPLAPharmaceuticalsChemicals
Market has likely priced in the initial sentiment; however, monitor policy developments and investment announcements in API manufacturing for long-term bullish plays on domestic pharma and chemical companies.
et_companies2 months ago+60

Work on reducing import dependence for raw materials: Commerce Secretary Rajesh Agrawal to pharma industry

sell5 factsSUNPHARMADRREDDYCIPLAPharmaceuticalsChemicals
Market has likely priced this in, but long-term investors should consider Indian pharma stocks with strong domestic manufacturing and R&D capabilities for sustained growth.